Introduction
============

Breast cancer is the most common types of cancer and the second leading cause of cancer-associated death in females worldwide, and accounts for \~500,000 deaths every year ([@b1-ol-0-0-11953]). Over 90% of breast cancer-associated deaths are primarily the result of metastasis ([@b2-ol-0-0-11953]). Despite recent advances in the diagnosis and treatment, 20--30% of patients with early-stage breast cancer remain at high risk of recurrence and metastasis ([@b3-ol-0-0-11953]). The bone has been identified as one of the predominant metastatic sites in patients with breast cancer and bone metastases account for 60--80% of patients with metastatic breast cancer (MBC) ([@b4-ol-0-0-11953],[@b5-ol-0-0-11953]). Furthermore, the bone is the most common site of initial distant metastatic spread in patients with breast cancer ([@b6-ol-0-0-11953]). Bone-only metastasis (BOM) is defined as a metastatic disease limited to the bone at the initial diagnosis of MBC. BOM is reported to occur in 25--40% of patients with MBC ([@b4-ol-0-0-11953],[@b6-ol-0-0-11953],[@b7-ol-0-0-11953]). Bone metastases are frequently complicated by skeletal-related events (SREs), including bone pain, pathological fractures, spinal cord compression and hypercalcemia, all of which are associated with a decreased survival time and quality of life ([@b8-ol-0-0-11953]--[@b10-ol-0-0-11953]).

Patients with BOM have unique clinical characteristics and prognostic outcomes compared with patients with other types of MBC. Hormone receptor (HR)^+^, human epidermal growth factor receptor 2 (HER2)^−^ and a low or intermediate histologic grade preferentially metastasize to the bone rather than the viscera ([@b11-ol-0-0-11953]--[@b13-ol-0-0-11953]). Patients with BOM exhibit longer survival times compared with patients with visceral metastasis or bone metastases combined with visceral metastases ([@b13-ol-0-0-11953],[@b14-ol-0-0-11953]). Previous studies determined that the median overall survival (OS) of patients with BOM from diagnosis of metastasis was 52--59 months ([@b7-ol-0-0-11953],[@b15-ol-0-0-11953],[@b16-ol-0-0-11953]).

Bone metastases from breast cancer are incurable and their clinical management is challenging. Bisphosphonates and denosumab have been used successfully to reduce the frequency of SREs of bone metastasis ([@b17-ol-0-0-11953]). Regrettably, bisphosphonate treatment is not able prevent the occurrence and development of bone metastasis ([@b18-ol-0-0-11953]). Palliative radiotherapy is effective in relieving bone pain caused by bone metastasis ([@b19-ol-0-0-11953]). Endocrine therapy, chemotherapy and sequential therapy (chemotherapy followed by endocrine therapy) may be used as alternative systemic therapies for these patients. However, it remains elusive which treatment method is able to prolong the survival time of patients with BOM the most. In addition, the current knowledge regarding prognostic factors for predicting outcomes among patients with BOM in China is limited.

The aim of the present retrospective study was to compare the clinical characteristics and prognosis between patients with BOM and non-BOM MBC. Outcomes were also compared among patients with different molecular subtypes with BOM or non-BOM. Survival and SREs of patients with BOM and different numbers of bone metastases and first-line treatment approaches were analyzed and the distribution of secondary metastatic sites in patients with BOM was determined. The conclusions of the present study may improve the current understanding of BOM and direct future guidelines for diagnosis and treatment selection. To the best of our knowledge, the present study is so far the largest study based on real-world data comparing the clinicopathological characteristics and prognosis of patients with breast cancer and BOM and non-BOM in China.

Patients and methods
====================

### Patient selection

Patients with MBC treated at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) between January 2008 and December 2017 were retrospectively analyzed. All patients were assigned to either the BOM or non-BOM group. Patients with the bone as the first and only site of metastasis at the time of MBC diagnosis were assigned to the BOM group. Patients with non-skeletal metastases (including non-skeletal combined with bone metastases) at the time of MBC diagnosis were assigned to the non-BOM group. A total of 1,290 patients were diagnosed with MBC; 208 (16.1%) had BOM and 1,082 (83.9%) had non-skeletal metastasis. Patients were required to have at least 6 months of follow-up. The median follow-up period was 26 months.

The inclusion criteria were as follows: ⅰ) Primary unilateral breast cancer that was pathologically diagnosed; ⅱ) female patients; ⅲ) metastatic disease pathologically diagnosed or diagnosed using an imaging technique \[e.g. bone scan, CT, MRI or positron emission tomography (PET)/CT\]; and ⅳ) relatively complete clinicopathological data and survival data. The exclusion criteria were as follows: ⅰ) Primary bilateral breast cancer; ⅱ) male patients; ⅲ) early breast cancer; ⅳ) coexistence of another malignancy; or ⅳ) patients with incomplete data. The present study was performed in accordance with all relevant guidelines, and the procedures were approved by the Tianjin Medical University Ethical Committee (Tianjin, China). The requirement of informed consent was waived due to the retrospective study design.

### Tumor subtype assessment and evaluation

To diagnose patients with metastatic disease, all patients included in the present study were examined using a whole-body imaging technique (e.g. B-ultrasound, CT, MRI or PET). Patients with a single bone metastasis were diagnosed by bone biopsy. Tumor types were classified as infiltrating ductal carcinoma or others. The clinical stages were classified according to the American Joint Committee on Cancer TNM staging system 7th edition ([@b20-ol-0-0-11953]). The expression status of progesterone receptor (PR), estrogen receptor (ER) and HER2 was assessed by initial immunohistochemical (IHC) analysis of a biopsy of the breast carcinoma. Breast cancer was divided into three major molecular subtypes: HR^+^/HER2^−^, HER2^+^ and HR^−^/HER2^−^. HR^+^ was defined as ER or PR ≥1% by IHC ([@b20-ol-0-0-11953]). Regarding HER2, IHC 1+ was considered as negative and IHC 3+ was considered as positive, while IHC 2+ was inconclusive and fluorescence *in situ* hybridization (FISH) was used to make a decision ([@b21-ol-0-0-11953]). In the case of discordance between IHC and FISH results, the FISH result was prioritized. All other samples were classified as negative on analysis. In addition, triple-negative breast cancer (TNBC) was negative for HR and HER2.

### Bone metastasis characteristics

The location of bone metastasis was determined by examining clinical records and imaging reports at the time of BOM diagnosis. Skull, sternum, rib, spine and pelvic bones were classified as axial bones. Forearm, arms, hands, thighs, shanks and foot bones were classified as appendicular bones. Single bone metastasis was defined as a solitary metastatic lesion confined to a single bone. Multiple bone metastases were defined as ≥2 lesions, including \>1 lesion in the same bone. Bone metastasis is incurable; it is almost impossible to remove tumors in a metastasized bone and then tumors tend to recur or metastasize to other organs ([@b22-ol-0-0-11953]). The metastasis-free interval (MFI) was defined as the interval between the first diagnosis of BOM and time of the second presentation with metastatic disease.

### Treatment modalities

Data on first-line treatment characteristics for 144 patients with BOM and HR^+^/HER2^−^ status, including administration of chemotherapy, endocrine therapy or sequential therapy (chemotherapy followed by endocrine therapy), were obtained. A total of 36 patients received chemotherapy, 33 endocrine therapy and 75 sequential therapy.

### Statistical analysis

Categorical variables used to quantify clinical characteristics are presented as frequencies and proportions. The mean and a Student\'s t-test were used to compare the age differences between the BOM and non-BOM groups. Pearson\'s χ^2^ tests and Fisher\'s exact tests were used to compare the differences between two groups. The primary endpoints of the present study were disease-free survival (DFS), progression-free survival (PFS) and OS from the time-point of diagnosis of BOM. DFS was defined as the time interval from the diagnosis of breast cancer to recurrence or metastasis. PFS was defined as the time interval from diagnosis of metastasis to progression, death or the last follow-up date, whichever occurred first. OS was defined as the time interval from diagnosis of metastasis to death or to the last follow-up date if patients were alive, whichever occurred first. DFS, PFS and OS curves were drawn using the Kaplan-Meier method and compared among groups using a log-rank test. Univariate analysis was performed by logistic regression. Cox proportional hazards model was used for multivariate analysis and to estimate the hazard ratio and 95% CIs. All statistical tests used were two-sided. P\<0.05 was considered to indicate a statistically significant difference. SPSS version 25.0 (IBM Corp.) and GraphPad Prism version 7 were used to analyze the data.

Results
=======

### Patient characteristics

The median age at breast cancer diagnosis in the BOM and non-BOM groups was 48 years (range, 24--72 and 21--78 years, respectively). The median ages at MBC diagnosis in the BOM and non-BOM groups were 50 years (range, 24--78 years) and 52 years (range, 25--80 years), respectively. The clinical and pathological characteristics of the patients in the two groups are presented in [Table I](#tI-ol-0-0-11953){ref-type="table"}. In total, 1,290 patients with MBC were enrolled in the present study, including 208 (16.1%) patients in the BOM group and 1,082 (83.9%) patients in the non-BOM group. Compared with the non-BOM group, patients with BOM were more frequently diagnosed as clinical stage IV in the first instance (P\<0.001), as well as HR^+^ (P\<0.001) and HER2^−^ (P=0.03). The metastatic lesions in non-BOM patients included the lungs (60.7%), liver (42.4%) and brain (4.6%).

The survival time of patients with BOM was longer than that of patients with non-BOM ([Fig. 1](#f1-ol-0-0-11953){ref-type="fig"}). The median DFS time of patients with BOM was 31 months, while that of patients with non-BOM was 15 months (P\<0.001; [Fig. 1A](#f1-ol-0-0-11953){ref-type="fig"}). The median PFS in patients with BOM and non-BOM was 19.9 and 9.0 months, respectively (P\<0.001; [Fig. 1B](#f1-ol-0-0-11953){ref-type="fig"}). The median OS in the BOM and non-BOM groups was 45 months (95% CI: 38.1-51.9) and 35 months (95% CI:32.7-37.2), respectively (P\<0.001; [Fig. 1C](#f1-ol-0-0-11953){ref-type="fig"}).

### Prognostic factors for patients with BOM

Univariate analyses indicated that the tumor stage, HR status, HER2 status, molecular subtypes and the number of bone metastases were associated with PFS (P\<0.05; [Table II](#tII-ol-0-0-11953){ref-type="table"}). HR status, molecular subtypes, location of bone metastasis and the number of bone metastases were associated with OS (P\<0.05; [Table II](#tII-ol-0-0-11953){ref-type="table"}). Additionally, bisphosphonates therapy and radiotherapy were not associated with PFS or OS in patients with BOM.

Multivariate analysis using Cox regression indicated that the HR status and the number of bone metastases were independent factors affecting the PFS of patients with BOM. HR^−^ and multiple bone metastases were significantly associated with shorter PFS of patients with BOM ([Table III](#tIII-ol-0-0-11953){ref-type="table"}). HR status, the number of bone metastases and location of bone metastases were independent factors affecting OS of patients with BOM. HR^−^, multiple bone metastases, as well as the combination of axial and appendicular bone metastases, were significantly associated with shorter OS of patients with BOM ([Table IV](#tIV-ol-0-0-11953){ref-type="table"}).

### Prognostic factors for non-BOM patients

Univariate analysis indicated that age at diagnosis of metastasis, tumor stage, HR status and molecular subtypes were associated with OS of non-BOM patients (P\<0.05; [Table V](#tV-ol-0-0-11953){ref-type="table"}). In the multivariate analysis, age at diagnosis of metastasis, HR status and tumor stage were independent factors affecting the OS of non-BOM patients ([Table VI](#tVI-ol-0-0-11953){ref-type="table"}). In non-BOM patients, HR^−^, age ≤35 years at diagnosis of metastasis or stage T3-4 were associated with poor prognosis.

### Survival analysis of patients with BOM and non-BOM with different molecular subtypes

Survival analyses of patients with BOM with different molecular subtypes indicated that compared with patients with HER2^+^ or HR^−^/HER2^−^, those with HR^+^/HER2^−^ had significantly improved DFS, PFS and OS. There was no significant difference in DFS, PFS or OS between patients with HER2^+^ and HR^−^/HER2^−^ (P=0.25, 0.83 and 0.25, respectively; [Fig. 2A-C](#f2-ol-0-0-11953){ref-type="fig"}).

Survival analyses of non-BOM patients with different molecular subtypes suggested that patients with HR^+^/HER2^−^ and HER2^+^ had significantly longer PFS and OS compared with those with HR^−^/HER2^−^. There was no significant difference in PFS or OS of patients with HER2^+^ and HR^+^/HER2^−^ (P=0.12 and P=0.28, respectively). Patients with HR^+^/HER2^−^ had significantly longer DFS compared with patients with HER2^+^ or HR^−^/HER2^−^. There was no significant difference in the DFS of patients with HER2^+^ and HR^−^/HER2^−^ (P=0.61; [Fig. 2D-F](#f2-ol-0-0-11953){ref-type="fig"}).

### Treatment outcomes

First-line treatment approaches for patients with BOM and HR^+^/HER2^−^ status included chemotherapy, endocrine therapy and sequential therapy. Of the total 144 patients with HR^+^/HER2^−^ BOM, 36 received chemotherapy, 33 received endocrine therapy and 75 received sequential therapy. The proportion of patients receiving taxane or anthracyclines was 91.7% (33/36) in the chemotherapy group and 96% (72/75) in the sequential therapy group. Among patients receiving endocrine or sequential therapy, the proportions of those receiving aromatase inhibitors was 63.4% (21/33) and 78.7% (59/75), the proportions of those receiving tamoxifen was 15.2% (5/33) and 8% (6/75), the proportions of those receiving fulvestrant was 12.1% (4/33) and 13.3% (10/75), and the proportions of those receiving palbociclib were 9.1% (3/33) and 0%. Premenopausal patients with endocrine therapy were all treated by ovarian function suppression. It is important to note that Chinese patients have different national conditions and medical policies to face. The medical insurance coverage rate in China is 97.5%, but patients have varying medical expenses according to different types of insurance ([@b23-ol-0-0-11953]). Palbociclib was approved by the Chinese Food and Drug Administration on July 31, 2018 ([@b24-ol-0-0-11953]); despite its approval, the high medical costs have limited its use in China. Only a small number of patients in the present study received palbociclib due to its late availability and high medical costs. Most patients preferred chemotherapy because it was relatively cheaper and was covered by health insurance. [Table VII](#tVII-ol-0-0-11953){ref-type="table"} presents the different treatments applied for patients with HR^+^/HER2^−^ BOM with different characteristics at diagnosis of metastasis. Patients with multiple bone metastases were more likely to receive sequential therapy (P\<0.001).

Among the patients with HR^+^/HER2^−^ tumors, those who received sequential therapy or endocrine therapy had longer PFS and OS compared with those who received chemotherapy. There was no significant difference in the survival of patients who received sequential therapy and endocrine therapy (P=0.53 and 0.48, respectively; [Fig. 3](#f3-ol-0-0-11953){ref-type="fig"}). Among the patients with a single bone metastasis, patients who received endocrine therapy and sequential therapy had longer PFS and OS compared with those who received chemotherapy. There was no significant difference in PFS or OS between sequential therapy and endocrine therapy (P=0.28 and 0.12, respectively; [Fig. 4](#f4-ol-0-0-11953){ref-type="fig"}). Among the patients with multiple bone metastases, patients who received endocrine therapy or sequential therapy had longer PFS and OS compared with those who received chemotherapy. There was no difference in PFS and OS between sequential therapy and endocrine therapy (P=0.43 and 0.33, respectively; [Fig. 5](#f5-ol-0-0-11953){ref-type="fig"}).

### Association between SREs and characteristics of bone metastases

Of the 208 patients with BOM, 131 (63%) were complicated by SREs; SREs were significantly associated with the number of bone metastases (P\<0.001; [Table VIII](#tVIII-ol-0-0-11953){ref-type="table"}). The incidence of SREs in patients with multiple bone metastases was significantly higher compared with that in patients with a single bone metastasis. The location of bone metastasis had no impact on the incidence of SREs. For patients with HR^+^/HER2^−^ tumors, there was no significant difference in the incidence of SREs among the different treatments.

### Distribution of the secondary distant metastatic site

Of the 208 patients with BOM, 109 (52.4%) developed a secondary distant metastasis and the median MFI was 21 months (95% CI: 17.2-24.8 months). Furthermore, of the 109 patients with a second distant metastasis, 25.7% had an MFI within 1 year and 56.0% had an MFI within 2 years. The most common metastatic site was the liver (51.4%), followed by the lung (30.3%) and brain (13.8%). The proportions of HR^+^/HER2^−^ and HER2^+^ patients with liver metastasis were 76.8 and 16.1%, respectively. The high-risk period of liver or lung metastasis was the first three years after diagnosis of bone metastasis and the high-risk period of brain metastasis was the first 2 years ([Fig. 6](#f6-ol-0-0-11953){ref-type="fig"}).

Discussion
==========

The present study was the largest real-world analysis comparing clinicopathological characteristics, survival and prognostic factors of patients with BOM and non-BOM MBC published to date, to the best of our knowledge, and may be of great significance for guiding clinical treatment and prediction of prognosis. Understanding the time and location of the second metastatic site may help guide the follow-up and reexamination of patients with BOM. The proportion of patients with clinical stage IV in the BOM group was significantly higher compared with that in the non-BOM group. A previous study indicated that the clinical stage was an independent risk factor for the incidence of bone metastasis in patients with breast cancer ([@b25-ol-0-0-11953]). The bone is the most common metastatic site of *de novo* MBC ([@b26-ol-0-0-11953],[@b27-ol-0-0-11953]). The 'seed-and-soil hypothesis' highlights the bone as the preferred site of metastatic development ([@b28-ol-0-0-11953]). In agreement with other studies ([@b13-ol-0-0-11953],[@b29-ol-0-0-11953]), the HR status and molecular subtypes were identified as important factors affecting the presence of BOM. HR^+^ status and in particular HR^+^/HER2^−^ (or luminal A) carcinoma was more likely to develop BOM ([@b11-ol-0-0-11953],[@b12-ol-0-0-11953],[@b29-ol-0-0-11953]--[@b31-ol-0-0-11953]). Patients with HER2^+^ or HR^−^/HER2^−^ carcinoma were more likely to develop visceral and cerebral metastases, which was similar to the results of earlier studies ([@b31-ol-0-0-11953]--[@b35-ol-0-0-11953]).

Prior studies indicated that the prognosis of patients with BOM was better compared with that of breast cancer patients with visceral or brain metastasis ([@b36-ol-0-0-11953]--[@b38-ol-0-0-11953]). The results of the present study were in agreement with this, as the DFS, PFS and OS of patients with BOM were significantly longer compared with those of patients with non-BOM. Patients with non-BOM had metastases, which were highly invasive and more prone to progression. Recent studies have reported median OS times of patients with BOM of 51--59 months ([@b7-ol-0-0-11953],[@b15-ol-0-0-11953],[@b16-ol-0-0-11953]), which was longer than the median OS time of the cohort of the present study. A reason for this difference may be that patients in developed countries have comparatively better access to healthcare and receive increased medical attention, which may prevent recurrence or metastasis. To a certain extent, Chinese patients have limited access to the latest drugs and high medical costs skew comparisons between cohorts from different countries.

In the present study, HR^+^ primary tumors were significantly and independently associated with improved prognosis for patients with BOM, in agreement with previous studies ([@b15-ol-0-0-11953],[@b16-ol-0-0-11953],[@b39-ol-0-0-11953]). The ER status was closely associated with the histological grade; highly differentiated tumors tended to have higher expression levels of ER ([@b40-ol-0-0-11953]), which may be due to improved prognosis of ER^+^ patients. The number and the location of bone metastases were independent prognostic factors affecting PFS and OS of patients with BOM in the present study. These results were similar to those of previous studies ([@b15-ol-0-0-11953],[@b41-ol-0-0-11953],[@b42-ol-0-0-11953]), in terms of multiple bone metastases, as well as combined axial and appendicular bone metastases being associated with unfavorable prognosis of patients with BOM. The location of bone metastasis had no impact on the incidence of SREs in this study. Patients with combined appendicular and axial metastases at BOM diagnosis had a significantly greater odds of experiencing bone pain compared with patients with metastases confined to axial locations ([@b42-ol-0-0-11953]), decreasing the quality of life of patients. The present study suggested that patients with appendicular bone metastasis had improved prognosis. Specifically, there were only 7 patients with BOM with appendicular bone metastasis alone, all of which were a solitary bone metastasis at the time-point of BOM diagnosis, and 3 patients received sequential therapy and 2 patients received endocrine therapy. It is probably due to the small number of patients with appendicular bone metastasis and the superior treatment received that these patients had a longer survival time. Another previous retrospective study on 91 patients with bone metastases suggested that bisphosphonates significantly prolonged OS of patients with breast cancer ([@b39-ol-0-0-11953]). However, bisphosphonates therapy was not associated with PFS or OS in patients with BOM in the present study. There may have been a selection bias in the previous study, as patients in good physical condition or those expected to survive for longer were more likely to receive bisphosphonates. In patients with MBC, bisphosphonates are able to prevent or delay SREs, but cannot prolong OS ([@b18-ol-0-0-11953],[@b43-ol-0-0-11953]--[@b45-ol-0-0-11953]). To clarify, denosumab had not been marketed in the Chinese mainland by the end of the present study, and thus, none of the patients in the present study were treated with denosumab for bone preservation.

Non-BOM patients aged ≤35 years at diagnosis of metastasis exhibited poorer prognosis compared with patients aged \>35 years. This may have been due to the carcinomas in younger patients being more invasive and aggressive. It remains elusive whether age at primary diagnosis influences outcomes. Purushotham *et al* ([@b46-ol-0-0-11953]) indicated a decrease in the risk of distant metastasis with increasing age. Hung *et al* ([@b47-ol-0-0-11953]) determined that patients aged \<35 years had a significantly higher risk of brain metastasis. Chen *et al* ([@b38-ol-0-0-11953]) suggested that older age significantly contributed to poor prognosis. In the present study, there were no associations between age at primary diagnosis and prognosis of patients with breast cancer. Patients with HR^−^ status had a particularly high risk and poor prognosis, similar to previous studies ([@b48-ol-0-0-11953]--[@b50-ol-0-0-11953]). Laohavinij *et al* ([@b51-ol-0-0-11953]) indicated that T4 was significantly associated with poor prognosis of patients with MBC. In patients of the present study with non-BOM, T3-4 vs. T1-2 carcinoma was associated with poor prognosis.

In the present study, the DFS of both patients with BOM and non-BOM with HR^+^/HER2^−^ status was significantly longer, which was similar to previous studies ([@b7-ol-0-0-11953],[@b33-ol-0-0-11953]). In a previous study, the median follow-up time was 80.8 months and the luminal A subtype had the highest 10-year DFS rate compared with luminal B, luminal/HER2, HER2 enriched and TNBC ([@b52-ol-0-0-11953]). In agreement with earlier studies ([@b7-ol-0-0-11953],[@b29-ol-0-0-11953]), patients of the present study with BOM and HR^+^/HER2^−^ had improved PFS and OS compared with patients with HER2^+^ or HR^−^/HER2^−^. A previous large retrospective study indicated that the luminal A subtype had the highest 10-year survival rate, followed by luminal B and luminal/HER2, while HER2 enriched and TNBC had the worst survival ([@b52-ol-0-0-11953]), which was similar to the results of the present study. Amongst the patients with non-BOM in the present study, the PFS and OS of the HR^+^/HER2^−^ and HER2^+^ types was superior to that of HR^−^/HER2^−^ cases. Patients with HER2^+^ breast cancer had relatively improved survival. Studies suggested that among patients with MBC, those with HER2^+^ tumors had the best prognostic outcomes, while those with HR^−^/HER2^−^ tumors had the worst prognosis ([@b12-ol-0-0-11953],[@b53-ol-0-0-11953]), possibly due to advances in anti-HER2 molecular targeted drugs.

A previous study indicated that the survival rate of patients with BOM of the HR^+^/HER2^−^ type treated with sequential therapy was significantly higher compared with those treated with chemotherapy or endocrine therapy alone ([@b16-ol-0-0-11953]). However, these results are different from those of the present study, according to which patients receiving endocrine or sequential therapy had longer PFS and OS times compared with patients receiving chemotherapy; however, there was no significant difference between outcomes of endocrine therapy and sequential therapy. The same results were obtained in subgroups of patients with a single bone metastasis or multiple bone metastases. As Chinese patients have limitations regarding the availability of the latest drugs and affordability of medical treatments, palbociclib was approved by the Chinese Food and Drug Administration on July 31, 2018 ([@b24-ol-0-0-11953]). There were only 3 patients receiving cyclin-dependent kinase 4/6 inhibitors (palbociclib) in the endocrine therapy group. In the present study, the impact of the time of diagnosis was not considered. Among the patients with BOM, only a small number received fulvestrant and palbociclib as the first-line endocrine therapy. Of note, certain patients with BOM may benefit from the rapid development of endocrine drugs in the future. Furthermore, the present study indicated that the number of bone metastases should be considered by the clinician when making a decision on treatment options. Due to limited availability of drugs, as well as the intense demand for relieving symptoms, several patients with multiple bone metastases prefer sequential therapy. However, in the present study, endocrine therapy alone was as effective as sequential therapy, and sequential therapy may result in more adverse reactions, including vomiting, leukopenia and alopecia. Therefore, endocrine therapy may be preferred for patients with HR^+^/HER2^−^ BOM.

Earlier studies suggested that major risk factors for SREs were age, menopausal status, clinical stage, tissue grade and molecular subtypes ([@b54-ol-0-0-11953],[@b55-ol-0-0-11953]). The number of bone metastases was significantly associated with SREs in the present study. The incidence of SREs in patients with multiple bone metastases was significantly higher compared with that in patients with a single bone metastasis. Kuchuk *et al* ([@b55-ol-0-0-11953]) indicated that patients with ≥5 bone metastases were more likely to have an SRE than those with \<5. Parkes *et al* ([@b42-ol-0-0-11953]) determined that multiple bone metastases were associated with increased pain.

Among the patients of the present study with BOM who developed secondary site metastases, the liver was the most common site, followed by the lung and the brain. According to previous studies, the liver was the most frequent organ of metastasis after bone metastasis in HR^+^ breast cancer patients ([@b11-ol-0-0-11953],[@b56-ol-0-0-11953]). Furthermore, patients with HER2^+^ tumors were more prone to liver metastasis ([@b32-ol-0-0-11953],[@b57-ol-0-0-11953]). In the present study, the majority of patients with liver metastasis were of the HR^+^ or HER2^+^ types. Thus, it is necessary to pay increasing attention to the possibility of liver and lung metastasis in the first three years after diagnosis, and to brain metastases in the first two years after diagnosis to detect metastasis as early as possible.

The present study had certain limitations. The cohort was based on patients from a single institution and may thus have different characteristics from those at other centers, limiting widespread generalizations. The present study was a retrospective study and there may have been selection bias. The systemic therapy included various drugs, doses and courses, and future studies using randomization designs for different treatment methods are required.

In conclusion, the prognosis of patients with BOM was better compared with that of non-BOM patients. HR^−^ tumors, chemotherapy alone, multiple bone metastases, and combined axial and appendicular bone metastases, were significantly associated with poor prognosis in patients with BOM. An age at metastasis or recurrence of ≤35 years, HR^−^ status and a tumor stage of T3-4 were significantly associated with a poorer prognosis of patients with non-BOM. For patients with BOM and HR^+^/HER2^−^ status, endocrine therapy alone achieved satisfactory results.
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![(A) Disease-free survival, (B) progression-free survival and (C) overall survival curves of patients in the BOM and non-BOM groups. BOM, bone-only metastasis.](ol-20-04-11953-g00){#f1-ol-0-0-11953}

![Kaplan-Meier survival curves stratified by molecular subtypes. (A) DFS, (B) PFS and (C) OS curves in BOM patients. (D) DFS, (E) PFS and (F) OS curves in non-BOM patients. DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; BOM, bone-only metastasis; TNBC, triple-negative breast cancer; HER2, human epidermal growth factor receptor 2; HR, hormone receptor.](ol-20-04-11953-g01){#f2-ol-0-0-11953}

![Kaplan-Meier survival curves stratified by treatment methods in HR^+^ BOM patients. (A) PFS and (B) OS curves stratified by treatment methods in HR^+^ BOM patients. HR, hormone receptor; PFS, progression-free survival; OS, overall survival; BOM, bone-only metastasis.](ol-20-04-11953-g02){#f3-ol-0-0-11953}

![Kaplan-Meier survival curves stratified by treatment methods in patients with a single bone metastasis. (A) PFS and (B) OS curves in bone-only metastasis patients with a single bone metastasis. PFS, progression-free survival; OS, overall survival.](ol-20-04-11953-g03){#f4-ol-0-0-11953}

![Kaplan-Meier survival curves stratified by treatment methods in patients with multiple bone metastases. (A) PFS and (B) OS curves in BOM patients with multiple bone metastases. PFS, progression-free survival; OS, overall survival; BOM, bone-only metastases.](ol-20-04-11953-g04){#f5-ol-0-0-11953}

![Distribution of the secondary new metastatic lesion sites in patients after bone-only metastasis diagnosis. The liver, lungs and the brain were the major organs involved. The numbers are decreasing with time because only newly diagnosed metastases are shown and some patients were dying.](ol-20-04-11953-g05){#f6-ol-0-0-11953}

###### 

Patient characteristics at the initial diagnosis of breast cancer in the BOM (n=208) and non-BOM (n=1,082) groups.

  Characteristic                                          BOM group     non-BOM group   P-value
  ------------------------------------------------------- ------------- --------------- ---------
  Median age at primary diagnosis (range), years          48 (24--72)   48 (21--78)     0.978
  Median age at metastasis or recurrence (range), years   50 (24--78)   52 (25--80)     0.262
  Menopausal status, n (%)                                                              0.062
    Premenopause                                          116 (55.8)    527 (48.7)      
    Postmenopause                                           92 (44.2)   555 (51.3)      
  Lymph node status, n (%)                                                              0.838
    Negative                                                61 (29.3)   325 (30.0)      
    Positive                                              147 (70.7)    757 (70.0)      
  Tumor stage, n (%)                                                                    0.392
    T1                                                      53 (25.5)   329 (30.4)      
    T2                                                    103 (49.5)    515 (47.6)      
    T3                                                      34 (16.3)   141 (13.0)      
    T4                                                      18 (8.7)      97 (9.0)      
  Clinical stage, n (%)                                                                 \<0.001
    I                                                       24 (11.5)   151 (14.0)      
    II                                                      75 (36.1)   447 (41.3)      
    III                                                     61 (29.3)   382 (35.3)      
    IV                                                      48 (23.1)   102 (9.4)       
  Tumor type, n (%)                                                                     0.273
    Invasive ductal carcinoma                             170 (81.7)    917 (84.8)      
    Others                                                  38 (18.3)   165 (15.2)      
  HR status, n (%)                                                                      \<0.001
    Negative                                                39 (18.7)   422 (39.0)      
    Positive                                              169 (81.3)    660 (61.0)      
  HER2 status, n (%)                                                                    
    Negative                                              171 (82.2)    814 (75.2)      0.030
    Positive                                                37 (17.8)   268 (24.8)      
  Molecular type, n (%)                                                                 \<0.001
    HR^+^/HER2^−^                                         144 (69.2)    538 (49.7)      
    HR/HER2^+^                                              40 (19.3)   268 (24.8)      
    HR^−^/HER2^−^                                           24 (11.5)   276 (25.5)      

HER2, human epidermal growth factor receptor 2; HR, hormone receptor; BOM, bone-only metastases.

###### 

Univariate analyses of the influence of clinical factors on the PFS and OS of patients with BOM.

                                                       PFS, %          OS, %                   
  ---------------------------------------------- ----- -------- ------ --------- ------ ------ ---------
  Age at primary diagnosis, years                                      0.246                   0.244
    \<35                                         25    14.4     4.8              49.9   21.8   
    35-60                                        153   31.9     14.7             64.4   41.3   
    ≥60                                          30    29.2     7.8              56.6   38.2   
  Menopausal status at primary diagnosis                               0.879                   0.740
    Premenopause                                 116   27.1     12.9             59.0   33.6   
    Postmenopause                                92    32.6     11.0             65.2   46.2   
  Lymph node status at primary diagnosis                               0.412                   0.785
    Negative                                     61    31.7     16.4             69.2   41.4   
    Positive                                     147   29.2     11.3             59.1   37.7   
  Tumor stage at primary diagnosis                                     0.040                   0.114
    T1                                           53    43.7     20.7             67.4   50.3   
    T2                                           103   20.6     13.2             59.6   37.0   
    T3                                           34    28.4     11.8             61.3   29.6   
    T4                                           18    39.9     0                62.2   23.3   
  Clinical stage at primary diagnosis                                  0.337                   0.476
    I                                            24    39.4     24.6             72.2   49.4   
    II                                           75    23.7     17.9             66.5   37.7   
    III                                          61    28.3     7.7              51.5   34.1   
    IV                                           48    37.0     5.9              64.1   37.6   
  Pathologic type at primary diagnosis                                 0.118                   0.149
    Invasive ductal carcinoma                    170   27.7     12.3             59.2   37.3   
    Others                                       38    40.4     15.9             75.3   49.6   
  HR status at primary diagnosis                                       \<0.001                 \<0.001
    Negative                                     39    9.6      4.8              30.5   13.1   
    Positive                                     169   34.7     14.9             69.3   45.3   
  HER2 status at primary diagnosis                                     0.032                   0.168
    Negative                                     171   32.3     13.5             66.5   42.4   
    Positive                                     37    19.5     10.4             40.0   25.4   
  Molecular subtype at primary diagnosis                               0.001                   \<0.001
    HR^+^/HER2^−^                                144   36.0     14.9             71.9   45.4   
    HR/HER2^+^                                   40    20.4     12.8             42.8   26.4   
    HR^−^/HER2^−^                                24    10.0     0                33.5   16.8   
  Bone radiotherapy                                                    0.977                   0.353
    No                                           131   29.3     12.4             59.2   36.3   
    Yes                                          77    30.4     13.6             66.7   42.3   
  Bisphosphonate therapy                                               0.967                   0.386
    No                                           23    30.4     13.0             51.1   33.7   
    Yes                                          185   30.0     13.0             63.0   40.2   
  Location of bone metastases at BOM diagnosis                         0.123                   0.003
    Axial                                        164   28.1     11.8             63.4   40.1   
    Appendicular                                 7     71.4     53.6             85.7   71.4   
    Axial and appendicular                       37    30.4     9.1              48.7   24.7   
  Number of bone metastases at BOM diagnosis                           0.035                   0.004
    Single                                       60    43.7     17.5             77.0   51.7   
    Multiple                                     148   24.4     11.2             56.1   33.3   

HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PFS, progression-free survival; OS, overall survival; BOM, bone-only metastasis.

###### 

Multivariate analysis of prognostic factors affecting progression-free survival of patients with BOM.

  Variable                                     Hazard ratio   95% CI      P-value
  -------------------------------------------- -------------- ----------- ---------
  HR status at breast cancer diagnosis                                    
    Negative                                   1.00           Reference   --
    Positive                                   0.63           0.40-0.92   0.027
  Number of bone metastases at BOM diagnosis                              
    Multiple                                   1.00           Reference   --
    Single                                     0.64           0.45-0.91   0.013

The factors with P\<0.05 in the univariate analysis in [Table II](#tII-ol-0-0-11953){ref-type="table"} were incorporated in the multivariate analysis. Tumor stage, HER2 status and molecular subtype at primary diagnosis were adjusted for. HR, hormone receptor; BOM, bone-only metastasis.

###### 

Multivariate analysis of prognostic factors affecting overall survival of patients with BOM.

  Variable                                       Hazard ratio   95% CI      P-value
  ---------------------------------------------- -------------- ----------- ---------
  HR status at breast cancer diagnosis                                      
    Negative                                     1.00           Reference   --
    Positive                                     0.54           0.32-0.90   0.020
  Number of metastases at BOM diagnosis                                     
    Multiple                                     1.00           Reference   --
    Single                                       0.62           0.40-0.96   0.031
  Location of bone metastasis at BOM diagnosis                              
    Axial and appendicular                       1.00           Reference   --
    Axial                                        0.65           0.41-1.02   0.062
    Appendicular                                 0.07           0.01-0.57   0.013

The factors with P\<0.05 in the univariate analysis in [Table II](#tII-ol-0-0-11953){ref-type="table"} were incorporated into the multivariate analysis. Molecular subtype was adjusted for. BOM, bone-only metastases; HR, hormone receptor.

###### 

Univariate analyses of prognostic factors affecting overall survival of patients with non-bone-only metastasis.

                                                       Overall survival, %          
  --------------------------------------- ------------ --------------------- ------ ---------
  Age at diagnosis of metastasis, years                                             0.008
    ≤35                                     85 (7.9)   36.0                  8.0    
    \>35                                  997 (92.1)   48.1                  23.9   
  Lymph node status                                                                 0.077
    Negative                              325 (30.0)   50.7                  26.4   
    Positive                              757 (70.0)   45.5                  21.7   
  Tumor stage                                                                       0.007
    T1-2                                  844 (78.0)   48.8                  25.1   
    T3-4                                  238 (22.0)   41.0                  15.5   
  Clinical stage                                                                    0.205
    I                                     151 (14.0)   49.4                  26.1   
    II                                    447 (41.3)   49.6                  25.7   
    III                                   382 (35.3)   44.1                  19.2   
    IV                                    102 (9.4)    42.1                  14.1   
  Pathologic type                                                                   0.437
    Invasive ductal carcinoma             909 (84.0)   45.7                  24.6   
    Others                                173 (16.0)   54.3                  18.6   
  HR status                                                                         \<0.001
    Negative                              422 (39.0)   36.4                  15.4   
    Positive                              660 (61.0)   54.3                  28.6   
  HER2 status                                                                       0.943
    Negative                              814 (75.2)   47.5                  23.2   
    Positive                              268 (24.8)   46.2                  23.6   
  Molecular subtype                                                                 \<0.001
    HR^+^/HER2^−^                         538 (49.7)   54.2                  28.0   
    HR/HER2^+^                            268 (24.8)   46.2                  23.6   
    HR^−^/HER2^−^                         276 (25.5)   34.5                  14.7   

HR, hormone receptor; HER2, human epidermal growth factor receptor 2.

###### 

Multivariate analysis of overall survival of patients with non-bone-only metastasis.

  Variable                                               Hazard ratio   95% CI      P-value
  ------------------------------------------------------ -------------- ----------- ---------
  Age at recurrence or metastasis (≤35 vs. \>35 years)   1.36           1.03-1.79   0.027
  HR status (negative vs. positive)                      1.55           1.32-0.81   0.027
  Tumor stage (T3-4 vs. T1-2)                            1.21           1.00-1.46   0.048

The factors with P\<0.05 in the univariate analysis in [Table V](#tV-ol-0-0-11953){ref-type="table"} were incorporated into the multivariate analysis. Molecular subtype was adjusted for. HR, hormone receptor.

###### 

Characteristics at initial diagnosis of metastasis in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative bone-only metastasis.

  Characteristic                       Chemotherapy, n (%)   Endocrine therapy, n (%)   Sequential therapy, n (%)
  ------------------------------------ --------------------- -------------------------- ---------------------------
  Total patients                         36 (25)             33 (22.9)                  75 (52.1)
  Age at metastasis diagnosis, years                                                    
    \<35                                 3 (8.3)               6 (18.2)                   0 (0.0)
    35-60                              25 (69.4)             25 (75.6)                  60 (80.0)
    ≥60                                  8 (22.2)              2 (6.1)                  15 (20.0)
  Location of bone metastasis                                                           
    Axial                                0 (0.0)               2 (5.7)                    2 (3.4)
    Appendicular                       29 (80.9)             25 (80.0)                  59 (79.3)
    Axial and appendicular               7 (19.1)              6 (14.3)                 14 (17.2)
  Number of bone metastases                                                             
    Single                               8 (22.2)            21 (63.6)                  12 (16.0)
    Multiple                           28 (77.8)             12 (36.4)                  63 (84.0)

###### 

Associations between SREs and characteristics of bone metastasis.

                                SREs                                     
  ----------------------------- ------------- ----------- ----- -------- ---------
  Number of bone metastasis                                     28.316   \<0.001
    Single                        21 (16)     39 (50.6)   60             
    Multiple                    110 (84)      38 (49.4)   148            
  Location of bone metastasis                                   0.314    0.855
    Appendicular                  5 (3.8)       2 (2.6)   7              
    Axial                       102 (77.9)    62 (80.5)   164            
    Appendicular and axial        24 (18.3)   13 (16.9)   37             
  HR^+^/HER2-BOM treatment                                      0.013    0.990
    Chemotherapy                  22 (25.3)   14 (24.6)   36             
    Endocrine therapy             20 (23)     13 (22.8)   33             
    Sequential therapy            45 (51.7)   30 (52.6)   75             

SREs, skeletal-related events; BOM, bone-only metastasis; HR, hormone receptor; HER2, human epidermal growth factor receptor 2.
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